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High-grade serous carcinoma (HGSC) is the most common and aggressive histotype 
of epithelial ovarian cancer (EOC), and it is the predominant histotype associated with 
hereditary breast and ovarian cancer syndrome (HBOC). Mutations in BRCA1 and 
BRCA2 are responsible for most of the known causes of HBOC, while mutations in 
mismatch repair genes and several genes of moderate penetrance are responsible for 
the remaining known hereditary risk. Women with a history of familial ovarian cancer 
or with known germline mutations in highly penetrant genes are offered the option 
of risk-reducing surgery that involves the removal of the ovaries and fallopian tubes 
(salpingo- oophorectomy). Growing evidence now supports the fallopian tube epithelia as 
an etiological site for the development of HGSC and consequently, salpingectomy alone 
is emerging as a prophylactic option. This review discusses the site of origin of EOC, the 
rationale for risk-reducing salpingectomy in the high-risk population, and opportunities 
for salpingectomy in the low-risk population.
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iNTRODUCTiON
In 2015, approximately 22,000 women in the United States were diagnosed with ovarian cancer and 
14,000 died from this devastating disease (1). Ovarian cancer is a heterogeneous disease that can be 
divided into three main types: sex cord stromal tumors, germ cell tumors, and epithelial ovarian can-
cer (EOC). EOC accounts for the vast majority of ovarian cancers and consists of different subtypes, 
namely, mucinous, endometrioid, clear cell, low-grade serous, and high-grade serous carcinoma 
(HGSC) (2). The various histotypes differ in epidemiology, etiology, and treatment. High-grade 
serous ovarian carcinoma is not only the most common subtype of EOC, accounting for 75% of cases, 
but also the most aggressive. Most women present at advanced stages (stage III or IV) at diagnosis, at 
which point the 5-year survival rate ranges between 20 and 40%. However, for patients with stage I 
disease, the 5-year survival rate exceeds 90% (3). Molecular and genetic data indicate that HGSC of 
the ovary may have a similar origin to HGSC of the fallopian tube and peritoneum, and therefore, it 
has been suggested that all the three be described collectively as HGSC (4). Of the patients diagnosed 
with a HGSC, 15–20% will have a known germline mutation in the highly penetrant homologous 
repair pathway genes, BRCA1 or BRCA2.
In the general population, the incidence of ovarian cancer is higher in white women than in 
women from other racial or ethnic groups, and survival rates at 12 years are better in Caucasian 
American women (38%) compared with African-American women (32%). Of interest, Hispanic 
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women (43%) and Asian women (52%) have higher survival 
rates. It is estimated that about 1 in 500 Americans have a muta-
tion in BRCA1 or BRCA2. The lifetime risk of developing ovarian 
cancer with germline mutations in BRCA1 and BRCA2 is 40–60 
and 11–27%, respectively (5–9). The burden of hereditary breast 
and ovarian cancer syndrome (HBOC) was previously thought 
to be confined to white women, particularly those of Ashkenazi 
Jewish descent. However, recent studies of different immigrant 
populations in the United States and in their respective countries 
of origin have identified pockets of women who bare a similarly 
high genetic burden as the Ashkenazi Jewish population. Women 
of Bahamian heritage, for example, are estimated to have 27.1% 
of breast cancer cases due to BRCA mutations (10, 11). The ovar-
ian cancer burden in these isolated high-risk populations is still 
unclear, but likely to be as high as those women of Ashkenazi 
descent. Other highly penetrant genes, such as PTEN and TP53, 
and moderately penetrant genes, such as PALB2, BRIP1, CHEK2, 
and ATM (12), are also associated with HBOC, albeit at lower 
frequencies than the prevalence of BRCA1 and BRCA2 muta-
tions. Norquist et al. recently reported RAD51C, RAD51D, and 
BARD1 as additional genes mutated in the germline of invasive 
serous ovarian cancer patients (12, 13). These data suggest that 
despite the growing list of genes involved in ovarian cancer pre-
disposition, 70–85% of the women diagnosed with HGSC have 
“sporadic” disease.
Ovarian cancer incidence and mortality among US women 
has declined in those aged 35–59 years due to earlier detection 
methods or changes in risk (3). Conversely, in Southern and 
Eastern Europe, there is a corresponding rise in incidence (14) as 
women reduce breastfeeding and have fewer children (decrease 
in parity), which are both known risk factors. A similar trend 
of  increasing incidence is expected in low–middle income 
 countries (14).
Screening methods with CA-125 and transvaginal ultrasound 
have proved mostly ineffective in decreasing mortality for sporadic 
HGSC and ovarian cancer in general (15, 16). Early detection has 
been and continues to be a challenge in ovarian cancer because 
the disease is habitually asymptomatic before peritoneal spread 
(17). However, with the identification of pockets of the popula-
tion at high risk for HBOC, there is an opportunity to reduce the 
burden of disease through increased and targeted genetic testing 
as well as screening and prevention measures for ovarian cancer 
risk reduction.
CeLL OF ORiGiN OF SeROUS OvARiAN 
CANCeR
Ovarian Surface epithelia
Prior to the reported observation of in situ carcinoma in the distal 
end of the fallopian tube of women undergoing prophylactic 
surgery, the ovary was thought to be the etiological site of high-
grade serous ovarian cancer. Now, there are two candidates for 
the cell of origin, namely, the fallopian tube epithelium (FTE) 
and the ovarian surface epithelium (OSE). Both share common 
mesodermal embryological origin and close anatomic proximity. 
The fallopian tube, along with the uterus, uterine endocervix, and 
superior aspect of the vagina are derived from an invagination of 
the celom known as the Mullerian or paramesonephric ducts. The 
OSE is derived from the mesothelial celomic epithelium that lines 
the primitive ovary (18).
The “incessant ovulation” hypothesis, proposed by Fathalla 
(19), suggested that continuous ovulatory cycles during the 
reproductive lifespan of a woman increase her risk of developing 
HGSC (19). He proposed that ovulation resulted in an increase 
in inflammation through which the secretion of cytokines, 
chemokines, bradykines, and hormones induce DNA damage 
via oxidative stress in the cortical inclusion cysts (CIC) observed 
in the ovary. These events, along with proliferation of the OSE, 
promote metaplastic changes leading to neoplastic transforma-
tion (2, 15, 19).
Xenografts of transformed OSE cell lines and genetic animal 
models have been used in an attempt to model HGSC in the 
absence of in  situ pre-neoplastic lesions in the ovary. Genetic 
mouse models deleting BRCA1, Rb1, and TP53 genes from the 
OSE resulted in leiomyosarcomas (20) and not HGSC. In contrast, 
targeted deletion of these genes in the fallopian tube epithelia 
of mice has led to the development of tumors genomically and 
pathologically similar to HGSC (21). The somatic mutational 
spectrum found in lesions associated with the ovary proper 
and neoplastic lesions have been shown to have KRAS, BRAF, 
CTNNB1, ARID1A, PTEN, PPP2R1A, and PIK3CA (22). These 
tumors rarely have TP53 mutations, which suggest a distinct 
etiology and natural history of tumorigenesis from that of HGSC.
Fallopian Tube epithelia
There is now substantial convincing clinical and molecular evi-
dence in support of the FTE as the source of the cell of origin of 
low- and high-grade serous ovarian cancer (22). Experimental 
in vitro manipulation and transformation of human fallopian tube 
epithelial cells have demonstrated that these cells in a xenograft 
model can give rise to tumors, which resemble primary HGSC 
(23). Additionally, mouse models targeting BRCA and TP53 in 
fallopian tube epithelia develop HGSC (21).
A series of transcriptional studies by Tone et al. and George et al. 
have shown that the phenotypically normal fallopian tube epithelia 
from BRCA1 and BRCA2 mutation carriers show transcriptional 
differences when compared to epithelial cells with a normal BRCA 
genotype. These differences have been shown to impact different 
molecular pathways. Consequently, these pathways are implicated 
in tumor initiation, progression, and recurrence (24–26). As a 
result of these studies, the authors proposed that chronic inflam-
matory states through cyclical ovulation in the presence of a 
mutated BRCA allele could predispose the normal FTE to undergo 
neoplastic transformation, which may lead to serous carcinoma. 
This would primarily occur through deregulation of DNA dam-
age response genes and synergistically through upregulation of 
cytokines, proinflammatory and proliferation genes.
The BRCA-associated carcinomas share some common 
genomic features such as frequent mutations of TP53 and copy 
number landscape features including Cyclin-E1 amplification 
and deletion of Rb1 (27). Altered BRCA function is not unique 
to hereditary HGSC but is prevalent via somatic mutations (6%) 
(28–31), promoter hypermethylation (13–31%) (28, 32–34), and 
TABLe 1 | evidence of serous tubal intraepithelial carcinoma in risk-
reducing salpingo-oophorectomy of asymptomatic women with known 
BRCA1 or BRCA2 mutations or strong family history of breast or ovarian 
cancer.
Reference Number of 
RRSO cases
incidence of STiC or occult 
carcinoma in the distal end of 
the fallopian tube
Colgan et al. (53) 60 5 (8.3%)
Piek et al. (41) 12 5 (41.6%)
Leeper et al. (55) 30 3 (10%)
Powell et al. (49) 67 4 (6%)
Carcangiu et al. (56) 50 4 (8%)
Finch, et al. (48) 159 7 (4.4%)
Callahan et al. (52) 122 7 (5.7%)
Shaw et al. (39) 176 15 (8%)
Hirst et al. (54) 45 4 (8.9%)
Powell et al. (59) 111 6 (5.4%)
Manchanda et al. (50) 117 10 (8.5%)
Mingels et al. (58) 226 16 (7.1%)
Reitsma et al. (60) 303 3 (0.99%)
Wethington et al. (62) 593 12 (2.0%)
Cass et al. (57) 78 9 (11.5%)
Sherman et al. (61) 966 25 (2.6%)
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other genetic or epigenetic alterations, predominantly in the 
homologous recombination (HR) pathway in HGSC. This has 
led to determining the “BRCAness” profile in patients (35, 36). 
Overall, these differences in morphologically normal epithelia 
from BRCA mutation carriers have shed light into the effects of 
heterozygosity and predisposition to the development of HGSC 
and, importantly, potential features that might be manifested in 
the STIC.
Detailed histopathological examination of tubal epithelia in 
BRCA mutation carriers undergoing risk-reducing surgery led to 
the discovery of putative cancer precursor lesions in the fallopian 
tube referred to as serous tubal intraepithelial carcinoma (STIC) 
(37–40). STIC was first reported by Piek et  al., who described 
dysplastic epithelial changes in the fallopian tubes of women with 
a BRCA1 or BRCA2 mutation, who underwent risk-reducing 
salpingo-oophorectomies (RRSO) (38, 41). These lesions have 
distinct morphological features such as loss of polarity, epithe-
lial tufting, and pleomorphic nuclei, and in addition, there is 
abnormal p53 expression and a high-proliferative index (refer to 
Lheureux et al. for commentary) (2, 42).
Since the discovery of the STIC, three possible pre-neoplastic 
lesions have been described, including the p53-signature, low 
grade serous tubal intraepithelial lesions (STIL), and secretory 
cell outgrowths (SCOUTS) (43). These lesions share a combina-
tion of phenotypic and/or genomic alterations with the cancer 
cells in HGSC. TP53 mutations, which are ubiquitous in HGSC, 
are usually concomitantly found in STIC and HGSC (2, 44). 
Over-expression of p16 has been documented in some STILS and 
over-expression of Pax8, Bcl-2, and loss of Pax2 expression has 
been observed in SCOUTS (45). However, none of these lesions 
are clinically actionable, as it is still unclear which of these lesions 
and/or combination of genomic alterations, has the pathogenic 
capacity to give rise to a carcinoma.
Many studies have now reported the incidence of non-invasive 
neoplastic lesions (STIC) in the distal end of the fallopian tube. 
It is estimated that occult invasive and STIC are identified in 
0.9–8.5% of women undergoing RRSOs (2, 39, 40, 43, 46–63) 
(Table 1). The frequency of STIC lesions increases with age and is 
lower with oral contraceptive use (64). It is important to note that 
the large range in estimates of the prevalence of occult and STIC 
lesions is reflective of the variances in diagnostic methodologies 
used by different centers and study groups (42).
Powell and colleagues reported that in a long-term follow-
up study of women diagnosed with non-invasive serous tubal 
epithelial carcinoma who underwent RRSO, 6% (1/17) recurred 
43  months after risk-reducing surgery compared to 43% of 
women who had unsuspected invasive carcinoma at time of 
surgery (65). There is a continued need to understand the effects 
of inflammation and hormones on the fallopian tube epithelia, 
relating to latency and the preferential sites of seeding, are critical 
for addressing prevention and risk-reduction strategies in geneti-
cally high-risk populations.
Opportunities for Ovarian Cancer Risk 
Reduction
Epidemiological data show that oral contraceptives, aspirin, 
and other non-steroidal anti-inflammatory drugs reduce the 
risk of ovarian cancer. In a meta-analysis as a primary preven-
tion mechanism by Havrilesky et  al., oral contraceptive pills 
use reduced ovarian cancer risk by 50% if used for more than 
10 years (66). Recently, aspirin use was associated with a reduced 
risk of ovarian cancer, especially among daily users of low-dose 
aspirin (67). These observations highlight the relationship 
between ovulation and its inflammatory accompaniment with 
ovarian cancer development. Women identified at highest risk, 
that is, germline mutation carriers and/or strong family history 
of ovarian cancer, may benefit from use of these chemopreven-
tion strategies.
Tubal ligation (tubal sterilization) has been shown to reduce 
ovarian cancer risk that theoretically is spread through retrograde 
menstrual flow (68–70). In particular, tubal ligation was associ-
ated with reduced risk of invasive ovarian cancer, with the great-
est benefit seen in the endometrioid and clear cell subtypes (71). 
The mechanism of protection is through prevention of retrograde 
menstruation, and hence, a decrease in Fenton’s reaction (gener-
ates reactive oxidative species) in the environment of the fallopian 
tube as well as prevention of endometrial cells implanting in the 
ovary. Although tubal ligation appears to be protective for all 
histotypes of ovarian cancer, it is least effective in reducing risk 
for the most lethal subtype, HGSC (71).
Salpingectomy
As early as 2002, Rebbeck et al. suggested that bilateral prophylac-
tic oophorectomies reduced the risk of ovarian and breast cancer 
in women with BRCA1 or BRCA2 mutations by as much as 96% 
(72). Olivier et  al. demonstrated that risk-reducing salpingo-
oophorectomy reduced the risk of ovarian, fallopian tube, and 
peritoneal papillary serous carcinoma in BRCA1 and BRCA2 
mutation carriers (some women still developed peritoneal dis-
ease) (73).
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As previously mentioned, there is clear evidence supporting 
the role of the fallopian tube as the etiological site of HGSC 
[and most likely low-grade serous carcinoma (22)]. For this 
reason, women with known risk for breast and ovarian cancer 
may undergo prophylactic surgical removal of the ovaries 
and fallopian tubes, a procedure known as RRSO. Current 
guidelines from the National Comprehensive Cancer Network 
and the Society of Gynecologic Oncologists suggest that RRSO 
to be completed by the post-child bearing period, the age of 
35–40, or 10  years younger than a first-degree relative diag-
nosed with ovarian cancer (74). However, it is believed that 
the majority of these high-risk women do not undergo RRSO 
by age 40 (75). This modality of precision prevention involves 
risk stratification and risk reduction in patients carrying both 
highly penetrant (76) (BRCA1 and BRCA2) and moderate to 
lower penetrant genes such as PTEN, PALB2, CHEK2, ATM, 
and BRIP1. The removal of the fallopian tubes alone is referred 
to as risk-reducing salpingectomy (RRS). In young women 
identified with a BRCA1 or BRCA2 mutation, RRS is performed 
in an effort to reduce ovarian cancer risk while maintain-
ing adequate hormonal levels to avoid the effects of early 
menopause. This latter approach, however, is not restricted to 
women at high risk for serous ovarian cancer, as it will also 
have a beneficial impact on reducing the risk of development of 
endometriosis-associated clear cell and endometrioid ovarian 
cancer (Figure 1).
Opportunistic Salpingectomy
Opportunistic salpingectomy refers to removal of the fallopian 
tubes in women who are not at an increased risk of developing 
ovarian cancer. In 2010, a population-based and institution-
wide study in British Columbia, Canada, was initiated whereby 
three recommendations to gynecological surgeons were made: 
(1) consider opportunistic salpingectomy during hysterectomy, 
(2) consider excisional bilateral salpingectomy rather than 
tubal ligation for sterilization, and (3) refer all HGSC patients 
for BRCA1/2 germline testing (77). Interim results on surgical 
outcomes revealed that the rates of hysterectomy with bilateral 
salpingectomy increased 3.5-fold compared to hysterectomy 
alone, and the rates of tubal ligation as a mode of surgical steril-
ity decreased from 99.7% in 2009 to 66.7% in 2011, while the 
rate of bilateral salpingectomy concomitantly increased 111-fold 
compared to 2009 rates (77). The authors also reported that the 
length of hospitalization post-hysterectomy and bilateral sal-
pingectomy was not longer than for hysterectomy alone and that 
there was no significant difference in the rate of blood transfusion 
or hospital readmission among these two groups. In addition, 
there was no significant difference in length of hospitalization 
or rate of transfusion for bilateral salpingectomy compared to 
tubal ligation.
The caveat to opportunistic salpingectomy is that even if 
implemented on a large scale, the true impact of ovarian cancer 
reduction will take years to be realized (77). It is also important 
to note that salpingectomy alone, unlike oophorectomy, does 
not reduce the risk of breast cancer by modulating levels of 
estrogen.
There is categorical evidence that RRSO reduces ovarian and 
breast cancer death and all-cause mortality (78, 79). There is 
currently no evidence that points to the outcome and impact 
of ovarian cancer risk reduction for two-stage procedure 
of salpingectomy followed by oophorectomy. In the United 
States, MD Anderson is conducting a clinical trial assessing 
prophylactic salpingectomy with delayed oophorectomy (80). 
A report from the Nurses’ Health Study concluded that com-
pared with ovarian conservation, bilateral oophorectomy at the 
time of hysterectomy for benign disease was associated with a 
decreased risk of breast and ovarian cancer but an increased 
risk of all-cause mortality (81, 82); therefore, one can stipulate 
FiGURe 1 | (A) High-grade serous carcinoma (HGSC) is the most common histologic type of cancer seen in the ovaries, fallopian tube, and peritoneum. (B) The 
fallopian tubes may act as a possible conduit for retrograde menstrual flow, which is theorized to induce the malignant transformation of cells via oxidative stress, 
inflammation, and hyperestrogenism. Further, endometriosis has been strongly linked with endometrioid ovarian carcinoma and clear cell ovarian carcinoma.
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that salpingectomy alone may be sufficient in the genetically 
“low-risk” population, while the overall benefit versus harm 
of these approaches requires close attention in the genetically 
high-risk population. Specifically, oophorectomy offers protec-
tion against breast cancer even after menopause and improves 
survival in those with breast cancer (83). As these prevention 
modalities are implemented, it is important that the goal 
of decreasing the incidence and burden of ovarian cancer is 
not at the expense of worsening the incidence and mortality 
of breast cancer in women who are at increased risk due to 
co-morbidities.
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